PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 29, 2026Science Immunology7 citations

Palmitate-induced mitochondrial damage restricts histone acetylation in CD8 T cells to impair antitumor immunity

View Full Paper
STSilvia TibertiSGSara GennariMRMartina Romeo

Key Points

  • To determine how palmitate affects CD8 T cell functionality and its implications for antitumor immunity.
  • Used in vitro assays to analyze the effects of palmitate on CD8 T cells
  • Evaluated mitochondrial metabolism and histone acetylation
  • Identified sphingosine kinase 2 as a mediator
  • Applied pharmacological inhibition of SPHK2 to assess reversibility of effects
  • Palmitate reduced mitochondrial metabolism in CD8 T cells
  • Histone acetylation and gene transcription for effector functions were impaired
  • Inhibition of SPHK2 restored mitochondrial functions and CTL activity
  • These interventions improved antitumor responses in experimental models

Abstract

Lipid accumulation in the tumor microenvironment is a hallmark of solid tumors, with increased palmitate (PA) availability fostering tumor progression. Although PA’s direct effects on cancer cells are well described, its impact on CD8 T cells cytotoxic T lymphocytes (CTLs) remains unclear. Here, we show that PA irreversibly impairs CTL mitochondrial metabolism, leading to the loss of effector functions and compromised antitumor immunity. PA-induced mitochondrial dysfunction reduced histone acetylation and chromatin accessibility, suppressing transcription of genes involved in T cell replication and effector programs. We identified sphingosine kinase 2 (SPHK2) as a key mediator of PA-induced dysfunction, with pharmacological inhibition of SPHK2 restoring mitochondrial fitness, rescuing CTL effector function, and promoting antitumor activity. These findings uncover a distinct mechanism by which PA drives immune evasion in tumors and highlight SPHK2 as a potential therapeutic target to enhance T cell–based immunotherapies.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Tiberti et al. (2026) studied this question.

synapsesocial.com/papers/69c8c3a8de0f0f753b39e8fdhttps://doi.org/10.1126/sciimmunol.aeb1459
Ask AI
Helpful
Bookmark
Share
View Full Paper